Seeking Alpha guest Bret Jenson joins Cheddar to discuss a company he thinks is very undervalued, Synergy Pharmaceuticals. This company's primary drug candidate is Trulance, which was approved for Chronic Idiopathic Constipation in January. Trulance has two important advantages over the market leader Linzess, which does around $160 million in quarterly sales. First, it can be taken at any time of the day whereas Linzess has to be taken before the first meal of the day. In addition, diarrhea occurs in approximately one in six individuals that take Linzess. The rate for Trulance is approximately a third of that. Given Trulance has price parity with Linzess, Jensen expects it to steal considerable market share in a growing part of the market.